White Paper

Three Options To Viral Vector Manufacturing Capacity

By Carol Houts, Vice President Quality and Business Strategy, Germfree; Peter Walters, Advanced Therapy Medicinal Product Subject Matter Expert, CRB; Ryan McDonough, PE, Senior Vice President of Project Operations, DPS; Steve Gravallese, Program Director, Cytiva; Joseph Makowiecki, Director of Business Development, Cytivia

GE Facilities
access the White Paper!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of ECM Connection? Subscribe today.

Subscribe to ECM Connection X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to ECM Connection

Please tell us more about you so that we can customize our newsletters to your specific interests:

Cytiva